Urinary thromboxane A2/prostacyclin balance reflects the pathological state of a diabetic.

[1]  Ken-ichi Suzuki,et al.  Elevation of the Thromboxane A2/Prostacyclin Ratio in Urine of Diabetic Mice Analyzed by Gas Chromatography/Selected Ion Monitoring , 1998 .

[2]  M. Gerritsen,et al.  Physiological and pathophysiological roles of eicosanoids in the microcirculation. , 1996, Cardiovascular research.

[3]  T. Hishinuma,et al.  Analysis of the thromboxane/prostacyclin balance in human urine by gas chromatography/selected ion monitoring: abnormalities in diabetics. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.

[4]  T. Hishinuma,et al.  Effect of diabetic sera on the conversion of eicosapentaenoic acid (EPA) to prostaglandin I3 by cultured bovine aortic endothelial cells. , 1995, Prostaglandins.

[5]  E. Araki,et al.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. , 1995, Diabetes research and clinical practice.

[6]  J. P. De La Cruz,et al.  Prostacyclin-thromboxane balance and retinal vascular pattern in rats with experimentally induced diabetes. , 1995, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[7]  T. Hishinuma,et al.  Analysis of 11-dehydrothromboxane B2 in human urine improved by use of gas chromatography/high-resolution selected ion monitoring with 18O2-labelled analogue as an internal standard. , 1994, Biological mass spectrometry.

[8]  T. Hishinuma,et al.  Microdetermination of 2,3-dinor-6-ketoprostaglandin F1 alpha in human urine using gas chromatography-high-resolution selected-ion monitoring. , 1994, Journal of chromatography. B, Biomedical applications.

[9]  L. Diemel,et al.  Aldose reductase inhibitors and their potential for the treatment of diabetic complications. , 1994, Trends in pharmacological sciences.

[10]  F. DeRubertis,et al.  Eicosanoids in the pathogenesis of the functional and structural alterations of the kidney in diabetes. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  H. Nawata,et al.  Effects of cilostazol, a phosphodiesterase inhibitor, on urinary excretion of albumin and prostaglandins in non-insulin-dependent diabetic patients. , 1993, Diabetes research and clinical practice.

[12]  D. Steinberg,et al.  Role of oxidized low density lipoprotein in atherogenesis. , 1991, The Journal of clinical investigation.

[13]  T. Onaya,et al.  Effects of aldose reductase inhibitors on prostacyclin (PGI2) synthesis by aortic rings from rats with streptozotocin-induced diabetes. , 1991, Prostaglandins, leukotrienes, and essential fatty acids.

[14]  R. Baker.  The eicosanoids: a historical overview. , 1990, Clinical biochemistry.

[15]  F. DeRubertis,et al.  Protein kinase C is activated in glomeruli from streptozotocin diabetic rats. Possible mediation by glucose. , 1989, The Journal of clinical investigation.

[16]  W. Smith,et al.  The eicosanoids and their biochemical mechanisms of action. , 1989, The Biochemical journal.

[17]  M. Lagarde,et al.  Metabolic interactions between eicosanoids in blood and vascular cells. , 1989, The Biochemical journal.

[18]  G. Davı̀,et al.  Are the vascular complications of diabetes mellitus preceded by an altered thromboxane/prostacyclin plasmatic ratio? , 1986, Medical hypotheses.

[19]  B. Wolf,et al.  Diacylglycerol accumulation and microvascular abnormalities induced by elevated glucose levels. , 1991, The Journal of clinical investigation.

[20]  J. Vane,et al.  The prostacyclin--thromboxane A2 balance: pathophysiological and therapeutic implications. , 1983, British medical bulletin.